YIL175W Antibody

What is YIL175W protein and why are antibodies against it important for yeast research?

YIL175W is a protein found in Saccharomyces cerevisiae (Baker's yeast, strain ATCC 204508/S288c), which serves as a critical model organism in molecular biology research. Antibodies targeting this protein are valuable tools for investigating protein expression, localization, and function within yeast cells. YIL175W antibodies allow researchers to detect and quantify this specific protein in various experimental contexts, supporting fundamental research on cellular processes in this model organism .

When designing experiments with YIL175W antibody, it's essential to understand that proper antibody selection and validation significantly impact experimental reproducibility. Studies have shown that poorly characterized antibodies contribute to irreproducible research results, with some analyses finding that hundreds of published studies may have used unsuccessful antibodies in Western blotting and immunofluorescence applications .

What applications can YIL175W antibody be used for in yeast research?

The YIL175W antibody has been validated for specific research applications:

The applications are determined by the antibody's specificity and sensitivity characteristics. When using this polyclonal antibody, it's important to note that validation has been specifically performed for Western blotting and ELISA applications to ensure proper antigen identification . For any untested applications, researchers should conduct preliminary validation experiments before proceeding with full-scale studies.

How should I properly store and handle YIL175W antibody to maintain its activity?

YIL175W antibody requires specific storage conditions to maintain its functionality:

Upon receipt, the antibody should be stored at -20°C or -80°C to preserve its activity. Repeated freeze-thaw cycles should be avoided as these can compromise antibody performance and lead to inconsistent experimental results . The commercial YIL175W antibody is typically supplied in a liquid form with a storage buffer containing 50% glycerol, 0.01M PBS (pH 7.4), and 0.03% Proclin 300 as a preservative .

For handling during experiments, maintain the antibody on ice when in use, and return to cold storage promptly after completing procedures. Proper antibody storage is critical for experimental reproducibility, as deteriorated antibodies can lead to weak signals or false-negative results in your experiments.

What information should I include when reporting the use of YIL175W antibody in scientific publications?

Scientific reproducibility requires comprehensive reporting of antibody details. When publishing research using YIL175W antibody, include the following information:

• Complete antibody identification: Name (YIL175W Antibody), supplier (e.g., Cusabio), catalog number (e.g., CSB-PA316803XA01SVG), host species (Rabbit), and clonality (Polyclonal)

• Validation evidence: Reference to validation profile or include validation data in supplementary materials

• Application-specific details: Specify which applications the antibody was used for, working dilution, incubation conditions, and detection methods

• Sample details: If working with multiple species or sample types, clearly link which antibodies were used with which samples

Example reporting format:
"Rabbit anti-YIL175W polyclonal antibody (Cusabio, catalogue number CSB-PA316803XA01SVG) was used for Western blotting at 1:1000 dilution as validated in (figure X or reference Y)"

This detailed reporting is increasingly required by journals and enables other researchers to accurately reproduce your experiments, addressing a significant challenge in scientific reproducibility .

How can I validate the specificity of YIL175W antibody for my particular experiments?

Antibody validation is crucial for ensuring experimental reliability. For YIL175W antibody, consider implementing these validation strategies:

Genetic validation approach: This gold-standard method involves testing the antibody against samples where the target protein is absent (knockout) compared to wild-type samples. For YIL175W, this would mean:

• Obtain a YIL175W deletion strain in S. cerevisiae

• Prepare protein extracts from both wild-type and deletion strains

• Run parallel Western blots with identical conditions

• A specific antibody should show signal in wild-type but not in the deletion strain

This genetic validation approach has shown superior reliability compared to orthogonal methods, with studies indicating that 57% of antibodies recommended based on genetic validation strategies could be confirmed using standardized protocols, compared to only 43% for antibodies validated using orthogonal approaches .

For immunofluorescence applications, genetic validation is particularly crucial, with research showing that 80% of antibodies validated with genetic strategies succeeded in confirmation tests, versus only 38% for those validated with orthogonal strategies .

Additional validation methods:

• Orthogonal validation: Compare results with another method that doesn't use antibodies (e.g., GFP-tagging)

• Independent antibody validation: Test multiple antibodies against the same target

• Preabsorption test: Pre-incubate antibody with purified antigen before staining to demonstrate specificity

Document all validation results thoroughly, as this evidence strengthens your research findings and publication quality.

What are the best practices for troubleshooting weak or non-specific signals when using YIL175W antibody?

When encountering issues with YIL175W antibody performance, systematic troubleshooting can identify and resolve problems:

For weak signals:

• Antibody concentration: Increase antibody concentration incrementally (e.g., 1:1000 → 1:500 → 1:250)

• Incubation conditions: Extend primary antibody incubation time (overnight at 4°C)

• Detection system: Switch to a more sensitive detection method

• Sample loading: Ensure adequate protein concentration (15-30 μg total protein for yeast lysates)

• Transfer efficiency: Verify protein transfer with Ponceau S staining

For non-specific binding:

• Blocking optimization: Test different blocking agents (5% BSA vs. 5% non-fat milk)

• Washing stringency: Increase wash buffer stringency (add 0.1% SDS or increase NaCl concentration)

• Antibody dilution: Use higher dilutions to reduce non-specific binding

• Preabsorption: Pre-incubate with non-specific proteins from the sample species

Methodological table for optimizing Western blot conditions:

Remember that batch-to-batch variability is a common issue with polyclonal antibodies, and in cases where variability has been found, reporting batch numbers in publications can help other researchers interpret and reproduce results .

How does the polyclonal nature of commercial YIL175W antibody affect experimental design and interpretation?

The polyclonal nature of commercial YIL175W antibody has significant implications for research applications:

Advantages:

• Multiple epitope recognition: Polyclonal antibodies recognize multiple epitopes on the target protein, potentially increasing detection sensitivity

• Robust to minor protein modifications: May still detect proteins with post-translational modifications or slight denaturation

• Cost-effective: Generally less expensive to produce than monoclonals

Limitations and considerations:

• Batch-to-batch variability: Each production lot may have different epitope specificities and binding affinities

• Background concerns: May exhibit higher background compared to monoclonal antibodies

• Finite supply: Once a specific batch is depleted, exact replacements are impossible

Research design considerations:

• Purchase sufficient antibody from the same batch for complete studies

• Include lot/batch numbers in laboratory records and publications

• Revalidate new batches before use in critical experiments

• Consider using recombinant antibodies for long-term projects requiring consistent reagents

Research has shown that polyclonal antibodies are more likely to exhibit batch-to-batch variability compared to monoclonal antibodies, which can affect experimental reproducibility . In large-scale antibody testing, recombinant antibodies have demonstrated more consistent performance across applications, with studies finding well-performing renewable (recombinant) antibodies for 77% of tested proteins in Western blotting applications .

What control samples should be included when working with YIL175W antibody?

Proper experimental controls are essential for interpreting results obtained with YIL175W antibody:

Essential controls for Western blotting:

• Positive control: Lysate from wild-type S. cerevisiae known to express YIL175W

• Negative control: Lysate from YIL175W knockout strain (genetic validation)

• Loading control: Probe for constitutively expressed yeast protein (e.g., actin, GAPDH)

• Primary antibody omission: To identify non-specific binding of secondary antibody

• Molecular weight marker: To confirm target band appears at expected size

Controls for immunoprecipitation:

• Input sample: A small portion of the pre-immunoprecipitation sample

• IgG control: Non-specific IgG from the same species as the YIL175W antibody

• No-antibody control: Beads only, to identify proteins binding non-specifically to beads

Research demonstrates that genetic controls, particularly knockout validation, provide the most reliable confirmation of antibody specificity. In a comprehensive study of antibody performance, researchers found that genetic strategies (using knockout cells) were superior for validating antibodies compared to orthogonal approaches, with 80% success rate for IF applications versus only 38% for orthogonal methods .

How can I quantitatively assess YIL175W protein levels in different experimental conditions?

Quantitative analysis of YIL175W protein requires careful experimental design and appropriate analytical methods:

Western blot quantification:

• Use a dilution series of recombinant YIL175W protein to create a standard curve

• Ensure signal is within linear detection range (avoid saturated bands)

• Normalize to loading controls (e.g., total protein via Ponceau S or housekeeping proteins)

• Use technical replicates (minimum of 3) for statistical validity

• Apply appropriate statistical tests for comparison between conditions

ELISA-based quantification:
The validated ELISA application of YIL175W antibody provides more precise quantification:

• Develop a standard curve using purified YIL175W protein at known concentrations

• Ensure samples fall within the linear range of the standard curve

• Include technical duplicates or triplicates

• Calculate protein concentration based on standard curve regression

Data presentation considerations:

• Present data as fold-change relative to control conditions

• Include error bars representing standard deviation or standard error

• Clearly state normalization method and statistical tests used

• Include representative images of blots alongside quantification

Reliable quantification depends heavily on antibody specificity and consistent performance. Research has shown that approximately 57% of antibodies recommended based on genetic validation strategies could be confirmed using standardized protocols, emphasizing the importance of validation for quantitative applications .

How should I interpret YIL175W localization data from immunofluorescence experiments?

While the YIL175W antibody product information doesn't specifically mention validation for immunofluorescence , researchers interested in protein localization studies should consider these guidelines:

Experimental design for localization studies:

• Validation requirement: Before interpreting localization data, rigorously validate antibody specificity for IF applications using YIL175W knockout controls

• Co-localization markers: Include markers for subcellular compartments to confirm localization patterns

• Z-stack imaging: Capture multiple focal planes to avoid misinterpretation of protein localization

• Live vs. fixed cells: Consider how fixation methods might alter protein localization

Interpretation guidelines:

• Compare localization pattern with published literature on YIL175W

• Ensure signal is absent in YIL175W knockout cells

• Quantify co-localization with organelle markers using appropriate coefficients (e.g., Pearson's, Manders')

• Consider physiological relevance of observed localization

Technical considerations:
Research indicates that IF applications are particularly challenging for antibody validation, with 39% of proteins lacking any successful antibody for IF in a comprehensive study . For IF applications specifically, genetic validation approaches are strongly recommended, as research shows they have a significantly higher success rate (80%) compared to orthogonal approaches (38%) .

What are the implications of YIL175W antibody cross-reactivity for multi-species studies?

Understanding cross-reactivity is crucial when designing studies involving multiple species:

Potential cross-reactivity considerations:

• Closely related yeast species: May show cross-reactivity due to protein sequence homology

• Distant species: Low probability of specific binding, but possible non-specific interactions

Testing cross-reactivity:

• Perform Western blots with lysates from multiple species

• Include positive control (S. cerevisiae) and negative controls (species lacking YIL175W homologs)

• Sequence analysis of homologous proteins can predict potential cross-reactivity

• Consider epitope mapping to identify conserved regions that might lead to cross-reactivity

When reporting research involving multiple species, it is essential to clearly link which antibodies were used with which species samples to avoid confusion . This approach improves experimental reproducibility and allows other researchers to accurately interpret and build upon your findings.

How can I optimize the use of YIL175W antibody for chromatin immunoprecipitation (ChIP) experiments?

While the commercial YIL175W antibody is not specifically validated for ChIP applications , researchers interested in this technique should consider:

Preliminary validation for ChIP:

• Verify antibody specificity via Western blot using knockout controls

• Perform preliminary ChIP with positive control regions

• Include negative control regions (unexpressed genes)

• Compare results with published ChIP-seq datasets if available

Optimization parameters for ChIP protocol:

• Crosslinking: Titrate formaldehyde concentration (0.75-1.5%) and time (10-20 minutes)

• Sonication: Optimize conditions to achieve 200-500bp fragments

• Antibody amount: Test multiple antibody concentrations (2-10μg per reaction)

• Washing stringency: Adjust salt concentration in wash buffers

Control samples:

• Input DNA (pre-immunoprecipitation)

• IgG control (non-specific rabbit IgG)

• Positive control antibody (e.g., antibody against histone modifications)

The success of ChIP applications heavily depends on antibody specificity and optimization for this particular technique. Research indicates that antibodies validated for one application may not perform well in others, reinforcing the need for application-specific validation .

What parameters should I optimize when using YIL175W antibody for co-immunoprecipitation of protein complexes?

For investigators studying protein-protein interactions involving YIL175W, co-immunoprecipitation (co-IP) optimization is essential:

Critical parameters to optimize:

Validation approaches:

• Confirm successful IP of YIL175W by Western blot

• Include negative controls (IgG, knockout lysate)

• Consider reciprocal co-IP with antibodies against suspected interaction partners

• Validate findings with orthogonal methods (e.g., proximity ligation assay)

Research on antibody performance found that for immunoprecipitation applications, investigators identified well-performing renewable antibodies for 75% of the proteins tested , suggesting that many proteins can be successfully studied using IP when appropriate antibodies and conditions are employed.

How can I determine if batch-to-batch variability affects my YIL175W antibody experiments?

Batch-to-batch variability is a significant concern with polyclonal antibodies and requires proactive management:

Testing for batch variability:

• Perform side-by-side Western blots with old and new antibody batches

• Use identical sample preparation, loading, and detection methods

• Compare signal intensity, background levels, and band patterns

• Quantify differences using densitometry analysis

Strategies to minimize impact:

• Purchase sufficient antibody from a single batch for complete study

• Validate each new batch before use in critical experiments

• Include lot/batch numbers in laboratory records and publications

• Consider switching to monoclonal or recombinant antibodies for long-term projects

Documentation requirements:
Research demonstrates that batch-to-batch variability is a common concern, particularly with polyclonal antibodies . Publications should include batch numbers when variability has been observed to help other researchers accurately interpret and reproduce results .

A comprehensive study of antibody performance found that researchers could identify well-performing renewable (recombinant) antibodies for 77% of tested proteins in Western blotting applications , suggesting that recombinant antibodies may offer a solution to batch variability concerns for many proteins.

How might advances in antibody development impact future research with YIL175W?

The landscape of research antibodies is evolving rapidly, with implications for future studies involving YIL175W:

Emerging antibody technologies:

• Recombinant antibody development: Moving from traditional polyclonal/monoclonal antibodies to recombinant production offers increased reproducibility and consistency

• Single-domain antibodies (nanobodies): Smaller antibody fragments that may offer improved access to epitopes and tissue penetration

• CRISPR-based validation: Improved knockout validation approaches using CRISPR technology for more reliable antibody characterization

Implications for YIL175W research:
A comprehensive analysis of the commercial antibody landscape indicates that approximately 1.6 million antibodies cover ~96% of human proteins, with 53% of human proteins covered by at least five renewable antibodies . This suggests that as antibody technologies advance, researchers working with YIL175W and other yeast proteins can expect more reliable and better-characterized research tools.

Research has demonstrated that recombinant antibodies often show superior performance consistency compared to traditional antibodies, with studies finding well-performing renewable antibodies for 77% of tested proteins in Western blotting applications . As these technologies mature, they may provide researchers with more reliable alternatives to current YIL175W antibodies.

What reporting standards should I follow to maximize reproducibility in YIL175W antibody-based research?

Reproducibility in antibody-based research requires comprehensive reporting:

Essential reporting elements:

• Complete antibody identification: Full details including supplier, catalog number, host species, clonality, and RRID (Research Resource Identifier) if available

• Validation evidence: Reference to validation profile or include validation data in supplementary materials

• Application-specific details: Specify each application the antibody was used for, with corresponding optimization parameters

• Batch information: Include lot/batch numbers, particularly when batch variability has been observed

• Control samples: Describe all controls used to establish specificity

• Detailed methodology: Include buffer compositions, incubation times/temperatures, and detection methods

Impact of inadequate reporting:
Studies have found that inadequate antibody reporting significantly impacts research reproducibility. Analysis of literature citations found that out of 2010 publications using antibodies tested for Western blotting, 632 (31.4%) used antibodies that did not specifically detect their target protein . Similarly, for immunofluorescence, 428 out of 548 publications (78.1%) used antibodies that could not be confirmed in validation tests .

Following comprehensive reporting guidelines not only improves experimental reproducibility but also increases the visibility and impact of your research, as well-annotated publications are easier for antibody databases and search engines to index .

What are the essential best practices for ensuring reliable results with YIL175W antibody?

Based on extensive research on antibody performance and reproducibility, researchers working with YIL175W antibody should follow these core best practices:

• Rigorous validation: Confirm antibody specificity using genetic approaches (knockout controls) before use in critical experiments

• Application-specific optimization: Determine optimal conditions for each specific application separately, as antibodies validated for one application may not perform well in others

• Comprehensive controls: Include positive controls, negative controls, and technical replicates in all experiments

• Batch management: Document batch numbers, purchase sufficient antibody for complete studies, and revalidate new batches

• Detailed reporting: Follow comprehensive reporting guidelines in publications to enable reproducibility, including antibody details, validation evidence, and specific methods

Research on antibody performance has shown that only a subset of commercially available antibodies perform as expected in various applications. A systematic study found that researchers could identify well-performing antibodies for 77% of tested proteins in Western blotting, 75% in immunoprecipitation, but only 54% in immunofluorescence . This underscores the importance of validation and optimization for each specific application.